Barriers to ADHD diagnosis and treatment core to minimising risk due to negative outcome: Study

New Delhi, Mar 21 (PTI) Potential barriers to diagnosis and treatment of Attention-Deficit / Hyperactivity Disease (ADHD) in middle-income countries is imperative to minimise risk of negative outcomes from the disorder, according to a new study published in The Lancet.

Globally, the multinational study found that ADHD medication consumption increased by 9.72 per cent per year, from 1.19 Defined Daily Dose / ter in die or three times a day (DDD/TID) in 2015 to 1.43 DDD/TID in 2019, across 64 countries representing approximately 62.4 per cent of the world's population.

The results also showed marked differences between geographical locations.